Coverage of PBH is split between bullish and cautious voices, and the dispersion is unusually wide. The most recently reported average price target sits near $67.80 (rounded to $68 here), according to figures cited by Yahoo Finance and StockAnalysis, based on roughly five to seven covering analysts. Most ratings carry a Buy or Outperform designation, with a minority at Hold and no Sell ratings reported.
Attributable individual targets tell a more divided story. PBH has seen Canaccord Genuity at $88, Oppenheimer at $72, Jefferies at $71 (Hold), and Sidoti at $80. Meanwhile, D.A. Davidson recently cut its target to $31 from $38, reflecting a far more cautious view after repeated guidance reductions. That spread—roughly $31 to the high $80s—means the average is less a consensus than a midpoint between analysts who see a recovery and those who see structural problems. Several targets are likely to be revised again following the November 2026 guidance cut, so the average should be read as a moving figure, not a guarantee.
The stock closed near $44.32, down about 16.8% in a single session after fiscal second-quarter results. Reaching $68 would require a move of roughly 53%, which is a very large advance by any standard—effectively retracing most of the decline from the 52-week high of $71.07.
The reported Q2 beat—adjusted EPS (earnings per share) of $1.13 versus about $1.07 expected, and revenue of $336.3 million, up 22.7% year over year—was overshadowed by guidance. Management lowered fiscal 2027 revenue to $1.28–$1.29 billion and adjusted EPS to $4.48–$4.55, citing renewed production variability for Clear Eyes eye drops at the Pillar5 facility. Organic revenue, excluding acquisitions, fell 1.6% in the quarter. With the shares sitting just above the 52-week low of $42.62, any path to $68 would require the company to first stabilize the eye-care supply chain and then demonstrate sustained organic growth.
Valuation is the clearest supporting factor. PBH trades at a forward P/E (price-to-earnings) ratio near 10–11, well below its longer-term average in the mid-teens, which could leave room for multiple expansion if execution stabilizes. Outside of Clear Eyes, the franchise is performing: management described healthy consumption at Dramamine, Fleet, Compound W, TheraTears, and Hydralyte, with double-digit e-commerce growth and a marketing tailwind from GLP-1-related gastrointestinal demand. The Breathe Right and LaCorium acquisitions are tracking to plan, and adjusted gross margin improved to 57.7% from 55.3%. If the eye-care brand returns to normal production in fiscal 2028 as targeted, analysts' more bullish scenarios assume the base business can support meaningful earnings recovery.
The repeated Clear Eyes disruptions are the central obstacle. This was the third consecutive call in which the eye-care narrative slipped, and the brand is now expected to contribute less than $20 million this year, with recovery pushed to fiscal 2028. Higher debt is a compounding risk: the acquisitions added roughly $1.1 billion of debt, leverage is projected near 4.0x, and interest expense roughly tripled. GAAP results deteriorated sharply (diluted EPS of $0.53 versus $0.86 a year earlier) because of inventory step-up amortization and remediation costs. Women's health products such as Monistat face declining category incidence, and one large e-commerce customer has shown order volatility. Sustained weak guidance or further supply setbacks would likely keep valuation multiples compressed.
The shares are testing a major support zone at the 52-week low of $42.62. A decisive break below that level would leave the stock at multi-year lows with little established support beneath. On the upside, the first meaningful resistance sits in the mid-to-high $50s, where the stock consolidated before the post-earnings slide, with the 52-week high of $71.07—just above the $68 target—serving as the long-term ceiling. The sharp single-day drop on elevated volume suggests the market is repricing the guidance cut, and any recovery toward $68 would first need to reclaim these overhead levels.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary and this figure is not a stated timeline for reaching $68. Investors should watch the next several quarterly reports for evidence that Clear Eyes production has stabilized and that organic revenue has returned to growth. Key items include updated fiscal 2027 guidance, free-cash-flow generation versus the reduced target of at least $265 million, progress reducing leverage, and any analyst revisions following the guidance cut. Broader consumer-health spending trends and retailer order patterns will also matter for the base business.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a stock like PBH that has just experienced a sharp repricing, automated signals can help traders track whether the trend is stabilizing or deteriorating without manually reviewing every data point. The tool is designed to help users discover opportunities, monitor existing positions, and spot changing trends more efficiently. Traders seeking a data-driven edge may find it useful to explore the AI Daily Buy/Sell Signals alongside fundamental research.
Reaching $68 would require Prestige Consumer Healthcare to climb roughly 53% from its current level, retracing most of a deep drawdown triggered by a third guidance cut tied to Clear Eyes supply problems. The case for the move rests on a low valuation, a mostly healthy brand portfolio, and acquisitions that are performing as planned. The case against it rests on repeated operational execution failures, rising debt and interest costs, and deteriorating organic growth. Analyst views span a wide range—from a cautious $31 to targets in the high $80s—so the $68 average reflects substantial disagreement rather than conviction. Whether the stock approaches that level will depend above all on restoring Clear Eyes production and returning the base business to organic growth, making the next few quarters' guidance the decisive catalyst.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PBH has been loosely correlated with ZTS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PBH | 1D Price Change % | ||
|---|---|---|---|---|
| PBH | 100% | +2.98% | ||
| ZTS - PBH | 36% Loosely correlated | +0.17% | ||
| ANIP - PBH | 31% Poorly correlated | +5.10% | ||
| PRGO - PBH | 30% Poorly correlated | -0.71% | ||
| ELAN - PBH | 29% Poorly correlated | -0.30% | ||
| HLN - PBH | 29% Poorly correlated | +1.00% | ||
More | ||||
| Ticker / NAME | Correlation To PBH | 1D Price Change % |
|---|---|---|
| PBH | 100% | +2.98% |
| Pharmaceuticals: Generic industry (81 stocks) | -5% Poorly correlated | +0.74% |